mucositis incidence and associated complications incidence of oral mucositis in patients receiving high-dose head and neck radiation
Incidence of World Health Organization (WHO) grade 3 or 4 oral mucositis in patients receiving high-dose head and neck radiation approaches 100%. Mucositis is one of the prime limiting factors of chemoradiation for advanced head and neck carcinoma, leading frequently to enteral nutritional support and use of morphinomimetics with the objective of maintaining dose intensity throughout the entire radiation regimen.
incidence of oral and gastrointestinal mucositis in patients undergoing hematopoietic stem-cell transplantation
Incidence of WHO grade 3 or 4 oral mucositis can be as high as 75% in patients undergoing hematopoietic stem-cell transplantation (HSCT), depending on the intensity of the conditioning regimen used and the use of methotrexate prophylactically to prevent graft-versus-host disease. Management of oral and gastrointestinal mucositis is one of the main challenges during the period of aplasia, with risk of sepsis related to degree of mucosal barrier breakdown and depth of marrow suppression.
incidence of mucositis associated with standard multi-cycle chemotherapy (with or without radiotherapy) for non-Hodgkin's lymphoma and breast, lung and colorectal cancers Data relative to risk of developing grade 3 or 4 oral mucositis and diarrhea are presented in Table 1 .
For all tumor sites, chemotherapy with 5-fluorouracil (5-FU), capecitabine or tegafur leads to a high rate (e.g. 20-50%) of alimentary tract mucositis. Recently reported phase I modeling of drug dose and sequence may be of benefit to future patients in this regard. Chemotherapy with methotrexate and other antimetabolites leads to a 20-60% rate of alimentary tract mucositis according to the drug's given dose per cycle.
Recent advances in cancer patient management, including utilization of molecularly targeted cancer therapies, are anticipated to strategically redefine cure rates and adverse event profiles in the coming years. Thus the impact of these agents on the risk of mucosal damage and diarrhea has yet to be described.
mucositis management guidelines
Oral and gastrointestinal mucositis management guidelines are summarized below.
oral mucositis guidelines basic oral care and good clinical practice Multidisciplinary development and evaluation of oral care protocols, and patient and staff education in the use of such protocols is recommended for reduction of severity of oral mucositis from chemotherapy and/or radiation therapy [III, B] . Interdisciplinary development of systematic oral care protocols is suggested. As part of the protocols, the use of a soft toothbrush that is replaced on a regular basis is also suggested consistent with good clinical practice. Patient-controlled analgesia with morphine is recommended as the treatment of choice for oral mucositis pain in patients undergoing HSCT [I, A]. Regular oral pain assessment using validated instruments for self-reporting is essential.
In addition to the evidence-based recommendations and suggestions published by the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology (MASCC/ISOO), it is relevant to note that topical anesthetics can provide short-term pain relief for oral mucositis on an empiric basis. Low-level laser therapy (LLLT) is suggested to reduce incidence of oral mucositis and its associated pain, in patients receiving high-dose chemotherapy or chemoradiotherapy before HSCT, if the treatment center is able to support the necessary technology and training [II, B] . LLLT may also become useful for management of mucositis caused by highdose head and neck radiation.
gastrointestinal mucositis guidelines basic bowel care and good clinical practice
In addition to the evidence-based guidelines below, basic bowel care should include maintenance of adequate hydration. In addition, consideration should be given to the potential for transient lactose intolerance and the presence of bacterial pathogens. These suggestions are consistent with good clinical practice.
radiotherapy: prevention
Use of 500 mg sulfasalazine orally twice daily is suggested to reduce the incidence and severity of radiation-induced enteropathy in patients receiving external beam radiotherapy to the pelvis [II, B] .
Amifostine is suggested in a dose of at least 340 mg/m 2 to prevent radiation proctitis in those receiving standard-dose radiotherapy for rectal cancer [III, B] . Oral sucralfate is not recommended to reduce related side-effects of radiotherapy. It does not prevent acute diarrhea in patients with pelvic malignancies undergoing external beam radiotherapy, and compared with placebo it is associated with more gastrointestinal side-effects, including rectal bleeding [ 
